Teva Pharmaceutical Industries Limited (TEV) — Capital Reinvestment Ratio
Teva Pharmaceutical Industries Limited (TEV) has a Capital Reinvestment Ratio of 0.12x as of December 2025, meaning it reinvests 0% of its operating cash flow (€1.16 Billion) in capital expenditures (€142.00 Million). Check Teva Pharmaceutical Industries Limited tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Teva Pharmaceutical Industries Limited Capital Reinvestment Ratio (2015–2025)
This chart tracks Teva Pharmaceutical Industries Limited's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see Teva Pharmaceutical Industries Limited (TEV) cash flow conversion.
Annual Capital Reinvestment Ratio for Teva Pharmaceutical Industries Limited (2015–2025)
Year-by-year Capital Reinvestment Ratio for Teva Pharmaceutical Industries Limited from 2015 to 2025. See Teva Pharmaceutical Industries Limited free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.30x | €1.65 Billion | €501.00 Million | ▼ -23.9% |
| 2024 | 0.40x | €1.25 Billion | €498.00 Million | ▼ -15.8% |
| 2023 | 0.47x | €1.16 Billion | €549.00 Million | ▲ +37.7% |
| 2022 | 0.34x | €1.59 Billion | €548.00 Million | ▼ -51.1% |
| 2021 | 0.70x | €798.00 Million | €562.00 Million | ▲ +48.2% |
| 2020 | 0.48x | €1.22 Billion | €578.00 Million | ▼ -32.3% |
| 2019 | 0.70x | €748.00 Million | €525.00 Million | ▲ +163.7% |
| 2018 | 0.27x | €2.45 Billion | €651.00 Million | ▼ -32.2% |
| 2017 | 0.39x | €2.23 Billion | €874.00 Million | ▲ +69.6% |
| 2016 | 0.23x | €3.89 Billion | €901.00 Million | ▲ +66.3% |
| 2015 | 0.14x | €5.54 Billion | €772.00 Million | — |